Prevention & Lipids
Cardiovascular prevention
Primary and secondary prevention strategies
Emerging pathwayAlso known as: CV prevention, ASCVD prevention, cardiovascular risk
1,587
Clinical questions
25
Evidence-backed
100
Claims analyzed
Prevention & Lipids
Primary and secondary prevention strategies
Synthesized from 25 evidence-backed clinical questions linked to this topic — 4 supporting the intervention, 1 still contested.
Does icosapent ethyl vs mineral_oil_placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefiticosapent ethyl vs mineral_oil_placebo · 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization)
1 studies (8,179 patients, 1 RCTs) provide moderate-certainty evidence for benefit of icosapent ethyl for 5-point MACE (CV death, non-fatal MI, non-fatal stroke, coronary revascularization, unstable angina) in Hypertriglyceridemia with cardiovascular risk.
Does icosapent ethyl vs mineral_oil_placebo affect Cardiovascular Mortality in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefiticosapent ethyl vs mineral_oil_placebo · Cardiovascular Mortality
1 studies (8,179 patients, 1 RCTs) provide moderate-certainty evidence for benefit of icosapent ethyl for Cardiovascular mortality in Hypertriglyceridemia with cardiovascular risk.
Does Influenza vaccination vs placebo improve outcomes in Patients at high cardiovascular risk or with recent myocardial infarction?
Low Certainty+ Favors benefitInfluenza vaccination vs placebo
6 studies (193,955 patients) provide low-certainty evidence for benefit of Influenza vaccination for the outcome in Patients at high cardiovascular risk or with recent myocardial infarction.
Does exercise vs placebo improve outcomes in cardiovascular risk-related conditions?
Low Certainty+ Favors benefitexercise vs placebo
4 studies (2,144 patients) provide low-certainty evidence for benefit of exercise for the outcome in cardiovascular risk-related conditions.
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does icosapent ethyl vs mineral_oil_placebo affect Cardiovascular Mortality in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefiticosapent ethyl vs mineral_oil_placebo · Cardiovascular Mortality
Does icosapent ethyl vs mineral_oil_placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Hypertriglyceridemia with cardiovascular risk?
Moderate Certainty+ Favors benefitCardiovascular Risk in Young Persons: Secondary or Primordial Prevention?
Annals of Internal Medicine — Berenson G — Aug 2010
Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People
Journal of the American Heart Association — Zoungas S — Nov 2024
Development and validation of a five-year cardiovascular risk assessment tool for Asian adults aged 75 years and older
BMC Geriatrics — Fu Y — Jan 2025
Effect of mobile-based cognitive behavior therapy (CBT) on lowering of blood lipid levels in atherosclerotic cardiovascular disease (ASCVD) patients: study protocol for a multicenter, prospective, randomized controlled trial
Trials — Hong X — Jun 2022
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Cardiovascular prevention (also known as CV prevention, ASCVD prevention, cardiovascular risk). Primary and secondary prevention strategies
Synapse tracks 2 specific clinical questions in Cardiovascular prevention, each synthesized independently from its own trial evidence. They include: "Does icosapent ethyl vs mineral_oil_placebo affect Cardiovascular Mortality in Hypertriglyceridemia with cardiovascular risk?"; "Does icosapent ethyl vs mineral_oil_placebo affect 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization) in Hypertriglyceridemia with cardiovascular risk?".
As of 2026-08-14, the scientific consensus on Cardiovascular prevention is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/cardiovascular-prevention.
Deterministic synthesis from Synapse's enriched corpus — 112 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Cardiovascular prevention paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Cardiovascular prevention papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
icosapent ethyl vs mineral_oil_placebo · 5-point MACE (CV death, non-fatal MI, non-fatal stroke, unstable angina hosp, coronary revascularization)
Highlights from the Manifesto on the Health Economics of Cardiovascular Disease Prevention
PharmacoEconomics — Ademi Z — Sep 2025